

Conclusie SKML LL rondzending		Conclusie	Toelichting conclusie
Acute Myeloid Leukaemia and Related Precursor Neoplasms		AML	<p>groen=frequent -negatief</p> <p>rood=soms +positief</p> <p>(+)=deel vd cellen w=weak</p> <p>/=of h+=heterogeen</p> <p>+HD=sterke expressie</p>
AML with balanced translocation/inversions			
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 (AML1-ETO)		AML t(8;21)	TdT ⁺ CD13+ CD15+ CD19+ CD33w CD34(+HD) CD56+ CD65+ cCD79a+ HLADR+ MPO+
AML with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); CBFB-MYH11		AML inv(16)	several blast populations: CD2+ CD4+ CD11b+ CD11c+ CD13+ CD14+ CD15+ CD33+ CD34+HD CD36+ CD64+ CD65+ CD117+ MPO+
AML with t(15;17)(q22;q12); PML-RARA		AML t(15;17)	CD11a-/w CD11b-/w CD13+ CD15-/w CD18-/w CD33+HD CD34-/w CD56+ CD64+ CD65-/w CD117+ HLADR-/w and Hypogranular variant: CD2+ CD34+
AML with t(9;11)(p22;q23); MLLT3-MLL (in children)		AML t(9;11) children	CD4+HD CD13w CD14w CD33+HD CD34w CD65+HD HLADR+HD
AML with t(9;11)(p22;q23); MLLT3-MLL (in adults)		AML t(9;11) adult	CD4+ CD11b+ CD11c+ CD14+ CD34+ CD36+ CD56+ CD64+ CD117+
AML with t(6;9)(p23;q34); DEK-NUP214 (DEK-CAN)		AML t(6;9)	TdT+ CD13+ CD15+ CD33+ CD34+ CD38+ CD64+ CD117+ HLADR+ MPO+
AML with inv(3)(q21;q26.2) or t(3;3)(q21;q26.2); RPN1-EV11		AML inv(3)	CD7+ CD13+ CD33+ CD34+ CD38+ CD41+ CD61+ HLADR+
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1		AML t(1;22)	TdT- CD7- CD13+ CD33+ CD34- CD36+ CD41+ CD42+ CD45- CD61+ HLADR- MPO-
AML with gene mutations			
AML with mutated NPM1		AML mNPM1	CD11b+ CD13+ CD14+ CD33+ CD34- CD68+ MPO+
AML with mutated CEBPA		AML mCEBPA	CD7+ CD11b+ CD13+ CD14- CD15+ CD33+ CD34+ CD56- CD64- CD65+ HLADR+
AML with myelodysplasia-related changes			
tAML (therapy related AML)			
AML, not otherwise specified			
AML with minimal differentiation		AML min dif	TdT+ cCD3- CD7+ CD11b- CD13+ CD14- CD15- cCD22- CD33+ CD34+ CD38+ CD64- CD65- cCD79a- CD117+ HLADR+ MPO-/(+)
AML without maturation		AML no mat	CD2+ cCD3- CD4+ CD7+ CD11b+ CD13+ CD14- CD15- CD19+ cCD22- CD33(+) CD34+ CD56+ CD64- CD65- cCD79a- CD117(+) HLADR+ MPO(+)
AML with maturation		AML mat	CD2- CD4- CD7+ CD11b+ CD13+ CD14- CD15+ CD19- CD33+ CD34(+)/+ CD56- CD64- CD65+ CD117(+)/+ HLADR(+)/+
Acute myelomonocytic leukaemia		AML MyeloMono	several blast populations: CD4(+) CD7+ CD11b(+) CD11c(+) CD13(+) CD14(+) CD15(+HD) CD33(+) CD34(+) CD36(+)/+ CD56+ CD64(+HD) CD65(+)/+ CD68(+)/+ CD117(+)/+ CD163(+)/+ HLADR+
Acute monoblastic leukaemia and Acute monocytic leukaemia		AML Mono	CD4+ CD7+ CD11b+ CD11c+ CD13+ CD14+ CD15+ CD33+HD CD34+ CD36+ CD56+ CD64+ CD65+ CD68+ CD117+ CD163+ HLADR+ MPO-/(+)
Acute erythroid leukaemia (erythroleukaemia (erythroid/myeloid))		AML Ery/Mye	erythroblasts: CD11b- CD11c- CD13- CD14- CD15- CD64- CD65- CD71w/+ CD235+/+ MPO- myeloblasts: TdT+ CD2+ cCD3- CD4+ CD7+ CD11b-/w CD13+/w CD14- CD15- CD19+ cCD22- CD33+/w CD34+ CD38+ CD56+ CD64- CD65- cCD79a- CD117+/w HLADR+ MPO-/w
Acute erythroid leukaemia (pure erythroid leukaemia)		AML pure ery	CD11b- CD11c- CD13- CD14- CD15- CD34- CD36+ CD41- CD61- CD64- CD65- CD117+ CD135+/w/- HLADR- MPO-
Acute megakaryoblastic leukaemia		AMKBL	TdT- CD7+ CD11b- CD11c- CD13+ CD14- CD15- CD33+ CD36+ CD41+ CD42+ CD45- CD61+ CD64- CD65- HLADR- MPO-
Acute basophilic leukaemia		ABL	TdT+ CD9+ CD11b+ CD11c- CD13+ CD14- CD22+ CD33+ CD34+ CD64- CD117- CD123+ CD203c+ HLADR+
Myeloid sarcoma			
Myeloid proliferations related to Down syndrome		Myepo Down	CD4w CD7+ CD13+ CD14- CD15- CD33+ CD34+ CD36+ CD41+ CD42+ CD56+ CD61+ CD71- CD117+ CD235a- MPO-
Blastic plasmacytoid dendritic cell neoplasm		BPCD	TdT+ CD4+ CD7+ CD43+ CD45RA+ CD56+ CD123+ CD303+ CLA+ CD68+ CD33+ CD2+ CD36+ CD38+ CD3- CD5- CD13- CD16- CD19- CD20- CD79a- TCL1+
Precursor Lymphoid Neoplasms			
B lymphoblastic leukaemia/lymphoma, not otherwise specified			
B-ALL/LBL, NOS		B-ALL/LBL	TdT+ CD10+ CD13+ CD19+ CD20+ cCD22+ CD22+ CD24+ CD33+ CD34+ CD45- cCD79a+
pro-B-ALL (early precursor B-ALL)		pro-B-ALL	TdT+ CD19+ cCD22+ cCD79a+
common ALL (intermediate stage B-ALL)		common ALL	CD10+ (see also B-ALL/LBL general)
pre-B-ALL (most mature precursor B-ALL)		pre-B-ALL	cμ+ (see also B-ALL/LBL general)
B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities			
B-ALL t(9;22) BCR-ABL1		B-ALL t(9;22)	TdT+ CD10+ CD13+ CD19+ CD25+ CD33+ CD117-
B-ALL t(v;11q23) MLL rearr.		B-ALL MLL	TdT+ CD10- CD15+ CD19+ cCD22+ CD24-
B-ALL t(12;21) TEL-AML1		B-ALL t(12;21)	CD9- CD10+ CD13+ CD19+ CD20- CD34+ CD66c-
B-ALL with hyperdiploidy		B-ALL hyperdyp	CD10+ CD19+ CD34+ CD45-
B-ALL with hypodiploidy		B-ALL hypodyp	CD10+ CD19+
B-ALL t(5;14) IL3-IGH		B-ALL t(5;14)	CD10+ CD19+
B-ALL t(1;19) E2A-PBX1		B-ALL t(1;19)	CD9+HD CD10+ CD19+ CD34- cμ+
T lymphoblastic leukaemia/lymphoma		T-ALL/LBL	TdT+ CD1a+ CD2+ cCD3+ CD3+ CD4+ CD5+ CD7+ CD8+ CD10+ CD13+ CD33+ CD34+ cCD79a+ CD99+ CD117+
T-ALL/LBL			
pro-T-ALL		pro-T-ALL	CD1a- CD2- cCD3+ CD4- CD7+ CD8- CD34+
pre-T-ALL		pre-T-ALL	CD1a- CD2+ cCD3+ CD4- CD7+ CD8- CD34+
cortical T-ALL		cortic-T-ALL	CD1a+ CD2+ cCD3+ CD4+ CD7+ CD8+ CD34-
medullary T-ALL		medul-T-ALL	CD1a- CD2+ cCD3+ CD3+ CD4+ CD7+ CD8+ CD34-
Acute Leukaemias of Ambiguous Lineage			
Acute undifferentiated leukaemia		AUL	TdT+ cCD3- CD19- cCD22- CD34+ CD38+ CD41- CD42- CD61- cCD79a- HLADR+ MPO-
Mixed phenotype acute leukaemia		MPAL	
Mixed phenotype acute leukaemia with t(9;22)(q34;q11.2) BCR-ABL1		MPAL MLL	CD10- CD15+ cCD22w CD19+ cCD79a plus also (myeloid/monoblastic)
Mixed phenotype acute leukaemia with t(v;11q23); MLL rearranged		MPAL B/M	CD10+ CD11c CD13+ CD14+ CD19+ CD20-/w cCD22+ CD33+ CD64+ cCD79a+ CD117+ MPO+
Mixed phenotype acute leukaemia, B/myeloid, NOS		MPAL T/M	CD2+ cCD3+ CD3+ CD5+ CD7+ CD10- CD11c+ CD13+ CD14+ CD19- CD20- cCD22- CD33+ CD64+ cCD79a-CD117+ MPO+
Mixed phenotype acute leukaemia, T/myeloid, NOS			
Mature B-cell neoplasms			
Chronic lymphocytic leukemia / small lymphocytic lymphoma		MBCN	CD5+ CD10- CD11cw CD19+ CD20+ CD22+ CD23+ CD43+ cCD79a+ CD79b-/w FMC7-/w IgDw IgMw
Monoclonal B-cell lymphocytosis CD5+		CLL/SLL	PB <5x10 ⁹ /L monoclonal B-cells with CLL phenotype and healthy (no cytopenie, lymphadenopathy or extramedullary tissue involvement)
Monoclonal B-cell lymphocytosis CD5-		MBL CD5+	PB <5x10 ⁹ /L monoclonal B-cells with non-CLL phenotype and healthy (no cytopenie, lymphadenopathy or extramedullary tissue involvement)
B-cell prolymphocytic leukaemia		MBL CD5-	CD5+ CD19+ CD20+ CD22+ CD23+ CD38+ cCD79a+ CD79b+ FMC7+ IgD+HD IgM+HD/-
Splenic marginal zone lymphoma		P-LL	CD5- CD10- CD20+ CD23- CD43- cCD79a+ CD103- IgD+ IgM+
Hairy cell leukaemia		SMZL	CD5- CD10- CD11c+HD CD20+HD CD22+HD CD23- CD25+ CD43- CD103+ CD123+ FMC7+ monotypic slg+HD
Splenic B-cell lymphoma/leukaemia, unclassifiable		HCL	
Splenic diffuse red pulp small B-cell lymphoma			
Hairy cell leukaemia variant		HCLv	CD11c+ CD19+ CD20+ CD22+ CD25- CD72+ cCD79a+ CD79b+ CD103+ CD123- FMC7+ slgG+HD
Lymphoplasmocytic lymphoma		LPL	abnormal B-lymphoid cells: CD5- CD10- CD19+ CD20+ CD22+ CD23- CD25+ CD38+ CD43- cCD79a+ CD103- IgD- IgM+ /IgG+ /IgA+
Plasma cell neoplasms			
Monoclonal gammopathy of undetermined significance		MGUS	abnormal plasmacytic cells: CD138+ clgM+ /clgG+ /clgA+
Plasma cell myeloma		PCM	normal plasma cells: CD19+ CD38+HD CD56- polyclonal
Plasma cell leukaemia		PCL	aberrant plasma cells: CD19- CD38+wHD CD56+ monoclonal clgG+ /clgM+ /IgD+ /clgA+ CD10+ CD19- CD20+ CD38+HD CD52+ CD56+ CD79a+ CD117+ CD138+ slg- monotypic clgG+ /clgM+ /IgD+ /clgA+ PB >2x10 ⁹ /L or >20% monoclonal plasma cells: CD56-

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
 Nodal marginal zone lymphoma
 Follicular lymphoma
 Mantle cell lymphoma
 Diffuse large B-cell lymphoma, not otherwise specified
 Burkitt lymphoma +/- leukaemia

Mature T-cell neoplasms

T-cell prolymphocytic leukaemia
 T-cell large granular lymphocytic leukaemia
 Chronic lymphoproliferative disorders of NK cells
 Aggressive NK cell leukaemia
 Adult T-cell leukaemia/lymphoma
 Mycosis fungoides
 Sézary syndrome
 Angioimmunoblastic T-cell lymphoma
 Anaplastic large cell lymphoma
 Peripheral T-cell lymphoma, not otherwise specified

MTCN

MALT	CD5+ CD10- CD11cw CD20+ CD21+ CD23- CD35+ CD43- cCD79a+ CD103- IgM+/IgA+/IgG+
NMZL	CD5- CD10- CD19+ CD20+ CD22+ CD23- CD43+ cCD79a+ IgD+
FL	CD5- CD10+ CD19+ CD20+ CD22+ CD23- CD43- cCD79a+ CD103- slg+
MCL	CD5+ CD10- CD23-/w CD43+ CD103- FMC7+ IgM+HD/IgD+HD lambda
DLBCL	CD5+ CD10+ CD19+ CD20+ CD22+ CD30+ CD38HD- CD43- CD138- cCD79a+ s/clgM+/lgG+/lgA+
Burkitt L	TdT- CD10+ CD19+ CD20+ CD22+ CD23- CD38+ CD43+ CD77+ IgM+/+HD with light chain restriction
T-PLL	TdT- CD1a- CD2+ CD3+/w CD4+ CD7+ CD8+ CD52+HD
T-LGLL	CD3+ CD4+ CD5w/- CD7w/- CD8+ CD16+ CD57+ TCR $\alpha\beta$ + TCR $\gamma\delta$ +
CLPD-NK	CD2w/- CD3- cCD3+ CD5+ CD7w/- CD8+ CD16+ CD56w CD57w/- CD94+HD CD161w
ANKCL	CD2+ CD3- CD11b+ CD16+ CD56+ CD57-
ATLL	CD2+ CD3+ CD4+ CD5+ CD7- CD8+ CD15+ CD25+HD CD30+
MF	CD2+ CD3+ CD4+ CD5+ CD7- CD8- TCRab+
SS	CD2+ CD3+ CD4+ CD5+ CD7- CD8- CD26- TCRab+
AITL	CD2+ CD3+ CD4+ CD5+ CD10+ CD20+
ALCL	CD2+ CD3- CD4+ CD5+ CD8- CD15(+) CD25+HD CD30+ CD43+ CD45+ CD45RO+
PTCL, NOS	CD4+ CD5-/w CD7-/w CD8+ CD10- CD15+ CD20+ CD30+ CD52+ CD56+ CD79a+